Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;21(6):e050324227669.
doi: 10.2174/0115701638279362240223070810.

In silico Evaluation of NO-Sartans against SARS-CoV-2

Negar Omidkhah  1   2 , Farzin Hadizadeh  1   2 , Razieh Ghodsi  1   2 , Prashant Kesharwani  3 , Amirhossein Sahebkar  1   4
Affiliations

In silico Evaluation of NO-Sartans against SARS-CoV-2

Negar Omidkhah et al. Curr Drug Discov Technol. 2024.

Abstract

Introduction: Numerous clinical trials are currently investigating the potential of nitric oxide (NO) as an antiviral agent against coronaviruses, including SARS-CoV-2. Additionally, some researchers have reported positive effects of certain Sartans against SARS-CoV-2.

Method: Considering the impact of NO-Sartans on the cardiovascular system, we have compiled information on the general structure, synthesis methods, and biological studies of synthesized NOSartans. In silico evaluation of all NO-Sartans and approved sartans against three key SARS-CoV- -2 targets, namely Mpro (PDB ID: 6LU7), NSP16 (PDB ID: 6WKQ), and ACE-2 (PDB ID: 1R4L), was performed using MOE.

Results: Almost all NO-Sartans and approved sartans demonstrated promising results in inhibiting these SARS-CoV-2 targets. Compound 36 (CLC-1280) showed the best docking scores against the three evaluated targets and was further evaluated using molecular dynamics (MD) simulations.

Conclusion: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations are necessary for the drug development process.

Keywords: COVID-19; NO-sartans; Nitric oxide; RNA.; SARS-CoV-2; cardiovascular system.

PubMed Disclaimer

References

    1. Siddiqi H.K.; Mehra M.R.; COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020,39(5),405-407 - DOI - PubMed
    1. Ahamad S.; Kanipakam H.; Birla S.; Ali M.S.; Gupta D.; Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M, using molecular docking and dynamics simulation studies. Eur J Pharmacol 2021,890,173664 - DOI - PubMed
    1. Dutta M.; Tareq A.M.; Rakib A.; Mahmud S.; Sami S.A.; Mallick J.; Islam M.N.; Majumder M.; Uddin M.Z.; Alsubaie A.; Almalki A.S.A.; Khandaker M.U.; Bradley D.A.; Rana M.S.; Emran T.B.; Phytochemicals from Leucas zeylanica targeting main protease of SARS-CoV-2: Chemical profiles, molecular docking, and molecular dynamics simulations. Biology 2021,10(8),789 - DOI - PubMed
    1. Nunes V.S.; Paschoal D.F.; Costa L.A.S.; Santos H.F.D.; Antivirals virtual screening to SARS-CoV-2 non-structural proteins. J Biomol Struct Dyn 2021,1-15 - PubMed
    1. Yadav R.; Chaudhary J.K.; Jain N.; Chaudhary P.K.; Khanra S.; Dhamija P.; Sharma A.; Kumar A.; Handu S.; Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 2021,10(4),821 - DOI - PubMed

MeSH terms

LinkOut - more resources